Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 
@ the Bell: Markets struggle to find ground
Mounting losses throughout the day weighed on Canada’s main stock index on Wednesday. The tech sector led losses, followed by mining, telecom, health care, and financials.Sponsored byU.S. stock-in... read article.
@ the Bell: Broad gains overcome energy weakness
Gains in the base metal, financial, and telecommunication sectors helped lift Canada’s main stock index higher on Tuesday. Health care declined, along with energy, which fell for a second session.... read article.
Buzz on the Bullboards: Defying market expectations
Most market reviews are throwing around the dreaded R-word, “recession” like it’s going out of style. Once again, news headlines indicate that the markets may be steering towards one. It turns out... read article.

No Bid. And we're not playing bridge

LIMINAL BIOSCIENCES INC (US: LMNL)            Real-time   Last: more

New Press Release - Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

$55.8M of cash and cash equivalents at June 30, 2022Discontinuation of fezagepras developmentNet loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021LAVAL, QC and CAMBRIDGE, England , Aug. 9, article.


Hi Gunner if you want to know something about the lawsuit, just do your own reasearch, It's public ! You are obviously a lazy guy. How much each complainant paid? Sorry but it's not your more


WRONG as usual.  Had some spec money in this but oh well.  Sometimes you win, sometimes you don't.  Unlike many of you who invested their returement savings hoping to hit a home more


Gunner... you never had skin in the game. You're probably very close to someone at Liminal. Your goal is to discredit the lawsuit. You'll never win. You can't change nothing with more

Thematica Insights Report & Investor Guide

Thematica Report: Exploring the opportunities in battery metals

The Market Herald launches Thematica’s latest report: Battery Metals. Understand how battery metals are driving the future. Download today!


LOL.  Is your lawyer Rudy, meeting at Four Seasons Landscaping. Hire Sherlock Holmes next time not Sherlock Homes the building contractor. Lawsuit going great, ROF.  rate and reply

Isn't that surreal?

this dirt was sticking around for such a long time and probably even last a couple of years they were able to find some naive suckers to buy into this "story". Spectacular failure, not more


Finally?! We've been saying this for over three years now! Where have you been? Doesn't take a Sherlock Homes to figure out Thomvest screwed investors. I advised to say away from more


Say it isn't so.  SB, balain, PLItheone all giving up on this finally.  ROF Black mamba had it right so many years ago.  This has been a 30 year scam making many execs more


Really the only surprise would be that the SP isn't sitting at an all time low. Thomvest's plan was to drive this into the ground, outcome close now! $3600. to $0.36 in three years. more


What do you mean by "day one" ? 15 years ago when they shifted from 1402 to 4050 ? Do you think it was a Prometic frame up where Thomvest were scruded as you were by them after ?  rate and reply


there is nothing left... preclinical molecules have no interest for thomvest. This will wind up. It will be interesting to see who owns IP for 4050 and it's derivatives. Was it all a more


Either through ignorance or satire you seem to be oblivious to the fact that these criminals unethically stole millions from the average retail investor! Thomvest stole a 2.5 billion dollar more


Amidst all your tantalizing but fake   ?.?,?.?.?.?.?.  you omitted the most significant rumour in circulation.  The results on nitrogen scavenging are so stunning that more


That would be negative news, but best to know safery tolerance....? There still seems to be scetchy info on Ryplazmin...lmnl own 30%...? Mfg plant....? The Antagonists switches...pre-clinical more


As speculated over 3 years ago these unethical pigs have now finally drove Prometic into the ground! After delisting in a couple of weeks Liminal will disappear like a fart in the wind as planed more

RE:Press release - all 4050 development discontinued

Well said!  rate and reply

Press release - all 4050 development discontinued

Penicillin as management used to call it has been discontinued. Someone is either lying now or were lying back in 2016/17. Wow, what a complete fraud. This company will wind up by end of August.  rate and reply

New Press Release - Liminal BioSciences Announces Discontinuation of Fezagepras Development

LAVAL, QC and CAMBRIDGE, England, July 21, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of fezagepras.The decision to discontinue the development of fezagepras is based on results from article.

RE:RE:Market Rotation

I can't even begin to comprehend how you can still trust management after the way they handled the company at the end of 2018 / beginning of 2019. Not only they did manage to fail more